Standard BioTools Inc. (LAB)

Market Cap	405.98M -0.1%
Revenue (ttm)	86.26M -3.7%
Net Income	78.21M
EPS	0.20
Shares Out	390.37M
PE Ratio	5.11
Forward PE	52.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	375,878
Open	1.080
Previous Close	1.090
Day's Range	1.030 - 1.100
52-Week Range	0.870 - 1.720
Beta	1.31
Analysts	Buy
Price Target	1.55 (+49.04%)
Earnings Date	May 5, 2026

About LAB

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneo...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 10, 2011
• Employees: 389
• Stock Exchange: NASDAQ
• Ticker Symbol: LAB
• Website: https://www.standardbio.com

Financial Performance

In 2025, Standard BioTools's revenue was $85.33 million, a decrease of -6.24% compared to the previous year's $91.01 million. Losses were -$74.90 million, -59.49% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for LAB stock is "Buy." The 12-month stock price target is $1.55, which is an increase of 49.04% from the latest price.

Price Target

$1.55

(49.04% upside)

Analyst Consensus: Buy